These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 8815489)
1. [P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix]. Toledo-Cuevas EM; García-Carrancá A Rev Invest Clin; 1996; 48(1):59-68. PubMed ID: 8815489 [TBL] [Abstract][Full Text] [Related]
2. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252 [TBL] [Abstract][Full Text] [Related]
3. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691 [TBL] [Abstract][Full Text] [Related]
4. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297 [TBL] [Abstract][Full Text] [Related]
5. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150 [TBL] [Abstract][Full Text] [Related]
6. Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059 [TBL] [Abstract][Full Text] [Related]
7. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118 [TBL] [Abstract][Full Text] [Related]
8. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer. Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681 [TBL] [Abstract][Full Text] [Related]
10. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Jiang M; Milner J Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116 [TBL] [Abstract][Full Text] [Related]
11. [Ha-ras and p53 gene mutations scanned by PCR-SSCP in premalignant and malignant lesions of the uterine cervix associated with human papillomavirus]. Alonio LV; Dalbert D; Picconi MA; Cervantes Vazquez G; García Carrancá A; Distefano AL; Mural J; Bartt O; Bazan G; Teyssie AR Medicina (B Aires); 2000; 60(6):895-901. PubMed ID: 11436698 [TBL] [Abstract][Full Text] [Related]
12. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770 [TBL] [Abstract][Full Text] [Related]
13. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. Rampias T; Sasaki C; Weinberger P; Psyrri A J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448 [TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus and disease mechanisms: relevance to oral and cervical cancers. Nair S; Pillai MR Oral Dis; 2005 Nov; 11(6):350-9. PubMed ID: 16269025 [TBL] [Abstract][Full Text] [Related]
15. Prevention of carcinoma of cervix with human papillomavirus vaccine. Gavarasana S; Kalasapudi RS; Rao TD; Thirumala S Indian J Cancer; 2000; 37(2-3):57-66. PubMed ID: 11876611 [TBL] [Abstract][Full Text] [Related]
16. Papillomavirus and p53. zur Hausen H Nature; 1998 May; 393(6682):217. PubMed ID: 9607756 [No Abstract] [Full Text] [Related]
17. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029 [TBL] [Abstract][Full Text] [Related]
18. The role of TP53 in Cervical carcinogenesis. Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117 [TBL] [Abstract][Full Text] [Related]
19. The early HPV16 proteins can regulate mRNA levels of cell cycle genes in human cervical carcinoma cells by p53-independent mechanisms. Fogel S; Riou G Virology; 1998 Apr; 244(1):97-107. PubMed ID: 9581783 [TBL] [Abstract][Full Text] [Related]
20. [Expression of VEGF, KDR, p53, E6 HPV16 and HPV18 in vulvar and cervix cancer]. Michalski B; Mazurek U; Olejek A; Kuśmierz D; Poreba R; Witek A; Wilczok T Wiad Lek; 2000; 53(5-6):240-6. PubMed ID: 10983377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]